Literature DB >> 16951145

Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.

Judy Wai Ping Yam1, Frankie Chi Fat Ko, Chung-Yiu Chan, Dong-Yan Jin, Irene Oi-Lin Ng.   

Abstract

Deleted in liver cancer 1 (DLC1) is a recently identified tumor suppressor gene frequently underexpressed in hepatocellular carcinoma (HCC). DLC1 encodes a Rho GTPase-activating protein domain that exhibits growth-suppressive activity in HCC cell lines. Our recent finding has revealed that inhibition of Rho-mediated actin stress fiber formation by DLC1 is associated with its growth inhibitory activity. In the present study, we identified tensin2 as the novel binding partner of DLC1. Tensin2 belongs to a new family of focal adhesion proteins that play key roles in cytoskeleton organization and signal transduction. Dysregulation of tensin proteins has previously been implicated in human cancers. Tensin2 is highly expressed in human liver. Introduction of tensin2 into HCC cell lines with low expression of tensin2 caused significant growth inhibition and induction of apoptosis. Tensin2 directly interacted with DLC1 in vitro and in vivo. Both proteins localized to punctate structures in the cytoplasm. Sequence analysis of DLC1 and tensin2 identified caveolin-1 binding motif in both proteins. In vivo immunoprecipitation study confirmed that both proteins indeed interacted with endogenous caveolin-1, which is the major structural component of caveolae. Our findings presented here suggest a new model for the action of DLC1 in hepatocytes, whereby DLC1-tensin2 complex interacts with Rho GTPases in caveolae to effect cytoskeletal reorganization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951145     DOI: 10.1158/0008-5472.CAN-05-2850

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.

Authors:  Xuan Cao; Courtney Voss; Bing Zhao; Tomonori Kaneko; Shawn Shun-Cheng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  Tensin1 positively regulates RhoA activity through its interaction with DLC1.

Authors:  Yi-Ping Shih; Peng Sun; Aifeng Wang; Su Hao Lo
Journal:  Biochim Biophys Acta       Date:  2015-09-28

4.  The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.

Authors:  Pratima Basak; Rachelle Dillon; Heather Leslie; Afshin Raouf; Michael R A Mowat
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

5.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

6.  The protein-tyrosine kinase Syk interacts with the C-terminal region of tensin2.

Authors:  Kyung D Moon; Xiaoying Zhang; Qing Zhou; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2011-10-12

7.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Authors:  Xuyu Yang; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Cancer Res       Date:  2011-03-03       Impact factor: 12.701

8.  Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation.

Authors:  Huina Liu; Huirong Shi; Yibin Hao; Guoqiang Zhao; Xiaofeng Yang; Yali Wang; Mei Li; Min Liu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

9.  Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.

Authors:  Yi-Chun Liao; Yi-Ping Shih; Su Hao Lo
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.

Authors:  Lo-Kong Chan; Frankie Chi Fat Ko; Irene Oi-Lin Ng; Judy Wai Ping Yam
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.